Detail akcie Illumina Inc online

Business Summary: Illumina, Inc. specializes in DNA sequencing and array-based technologies, serving customers in research, clinical and applied markets. The Company's products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. Its comprehensive line of products addresses the scale of experimentation and breadth of functional analysis to advance disease research, drug development, and the development of molecular tests. It also specializes in data-driven proteomics technology. Its products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing services, microarray services, proactive instrument monitoring, and instrument services and training.
Financial Summary: BRIEF: For the three months ended 29 March 2026, Illumina Inc revenues increased 5% to $1.09B. Net income increased 2% to $134M. Revenues reflect Consumables segment increase of 4% to $797M, Services and Other revenue segment increase of 8% to $174M, Europe segment increase of 22% to $356M, Americas segment increase of 4% to $590M. Net income was partially offset by Other expense, net - Balancing value decrease of 67% to $10M (income).